CAS 172822-29-6

Aprepitant Related Compound B (3-[[(2S,3R)-2-[(S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one)

CAS: 172822-29-6

Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoi

Fórmula: C₂₃H₂₁F₇N₄O₃

Cor e Forma: White Off-White Crystalline Powder

Peso molecular: 534.15019

Ref: 45-1041926

ent-Aprepitant

CAS: 172822-29-6

Fórmula: C₂₃H₂₁F₇N₄O₃

Cor e Forma: White To Off-White Solid

Peso molecular: 534.43

Ref: 4Z-A-325

3-[[(2S,3R)-2-[(S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one ((S,R,S)-Aprepitant)

Produto Controlado

CAS: 172822-29-6

Fórmula: C₂₃H₂₁F₇N₄O₃

Cor e Forma: Neat

Peso molecular: 534.43

Ref: 86-MM3251.02

Aprepitant USP Related Compound B

CAS: 172822-29-6

Fórmula: C₂₃H₂₁F₇N₄O₃

Peso molecular: 534.43

Ref: ST-EA-CP-A109008

ent-aprepitant

CAS: 172822-29-6

Aprepitant is a drug that belongs to the class of antiemetics. It is an antagonist of the neurokinin-1 receptor (NK-1R) and blocks the apical portion of the NK-1R, preventing binding of substance P. Aprepitant also has been shown to have a matrix effect on human pharmacokinetics in vitro and to inhibit p450 activity in human serum. This drug has been found to induce apoptosis by inhibiting the expression of pro-apoptotic proteins and activating pro-survival proteins. Aprepitant has also been shown to be effective in treating solid tumours, particularly colorectal cancer, with synergism with chemotherapy drugs such as trifluoroacetic acid.

Fórmula: C₂₃H₂₁F₇N₄O₃

Pureza: Min. 95%

Cor e Forma: White To Off-White Solid

Peso molecular: 534.43 g/mol

Ref: 3D-FE22679

ent-Aprepitant-13C15N2

Produto Controlado

CAS: 172822-29-6

Fórmula: CC₂₂H₂₁F₇₁₅N₂N₂O₃

Cor e Forma: Neat

Peso molecular: 537.406

Ref: TR-A729792

ent-Aprepitant

Produto Controlado

CAS: 172822-29-6

Fórmula: C₂₃H₂₁F₇N₄O₃

Cor e Forma: Neat

Peso molecular: 534.43

Ref: TR-A729790